ZY - ZY STOCK NEWS

Ginkgo Bioworks (NYSE: DNA) has announced a definitive agreement to acquire Zymergen (Nasdaq: ZY) in an all-stock deal valued at approximately $300 million. Zymergen stockholders will receive 0.9179 Ginkgo shares per Zymergen share, resulting in a pro forma ownership of 5.25% in the combined entity. This acquisition aims to enhance Ginkgo's horizontal synthetic biology platform through Zymergen's technology and assets, fostering new growth opportunities. The transaction is expected to close by Q1 2023, pending regulatory and stockholder approvals.

Zymergen Inc. has announced an expanded agreement with Octant to enhance its drug discovery platform through the acquisition of six additional Reconfigurable Automation Carts (RACs). This expansion follows Octant's initial purchase of five RACs, effectively doubling its investment. The increased scale aims to improve throughput, efficiency, and reliability in developing breakthrough medicines for challenging diseases. Zymergen's automation technology incorporates cloud software to optimize lab operations and can be reconfigured rapidly for various applications.

Zymergen has partnered with 3D4Makers to supply Zymergen Z2 polyimide powder for high-performance 3D printing applications. This agreement allows 3D4Makers to convert the powder into filament, broadening its product line for aerospace, automotive, and transportation sectors. Zymergen Z2 polyimide offers high strength, flame retardancy, and excellent thermal stability, outperforming traditional materials. Industry leaders such as miniFactory have tested the material positively. Although details of the agreement remain undisclosed, it signifies Zymergen's commitment to innovative, bioinspired materials.

Zymergen has entered an agreement with Octant to provide a modular automation system aimed at enhancing Octant's drug development platform. This multi-phase partnership will integrate Zymergen’s complete automation solution, including hardware and software, into Octant's existing systems, allowing for increased workflow efficiency. The initial installation will consist of 5 Reconfigurable Automation Carts, with future expansions planned. This marks Zymergen’s first customer agreement following the commercial launch of its automation technology earlier in 2022.

Zymergen reported preliminary financial results for Q1 2022, with total revenue reaching $4.8 million, largely from R&D service agreements and collaborations. However, the company faced significant challenges, posting total operating expenses of $68.4 million and a net loss of $72.1 million during the quarter. As of March 31, 2022, Zymergen held $337.0 million in cash and cash equivalents. The results, while preliminary and unaudited, may change upon finalization.

A conference call will be held on May 12, 2022, to discuss these results.

Zymergen, a biotech firm based in Emeryville, California, will participate in the BofA Securities 2022 Healthcare Conference in Las Vegas on May 10 at 10:55 a.m. PT. The event will be accessible via a live and archived webcast on the company’s website. Zymergen specializes in designing and producing innovative molecules, microbes, and materials aimed at various markets, emphasizing a sustainable partnership with nature for better products. Investors can find further information in the 'Investors' section on their website.

Zymergen Inc. announced it will report preliminary financial results for Q1 2022 on May 12, 2022, after market close. The management will host a conference call at 1:30 PM Pacific Time / 4:30 PM Eastern Time to discuss these results. Investors can access the webcast via the company’s investor relations page. Zymergen specializes in designing and producing innovative molecules, microbes, and materials for various markets, emphasizing sustainable practices and partnerships with nature.

Zymergen has reported preliminary financial results for Q4 and full year 2021. Total revenue for Q4 was $3.0 million, with a full-year revenue of $16.7 million, primarily from R&D service agreements. Operating expenses for Q4 reached $74.3 million, including $7.6 million in restructuring charges, resulting in a net loss of $78.1 million. For the full year, total operating expenses were $364.3 million, with a net loss of $361.8 million. As of December 31, 2021, cash and cash equivalents stood at $386.1 million. The financial figures are preliminary and subject to finalization.

Zymergen Inc. will report preliminary financial results for Q4 and full year 2021 on March 22, 2022, after market close. The company's management will hold a conference call at 1:30 PM PT to discuss these results and future outlook. Zymergen focuses on creating molecules and materials through biotechnology, aiming to improve product offerings across various markets.